What Should You Discuss with Your Doctor About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one has taken Reglan and noticed unusual, uncontrollable movements, you may be concerned about tardive dyskinesia. This condition, linked to long-term use of the drug, can persist even after stopping the medication. Building on decades of pharmacovigilance research, this page outlines what current California studies reveal about the risk and how to monitor for symptoms.

Bridging to Reglan and Tardive Dyskinesia

The bridge concept emerges naturally: from the broad dissemination of health and science facts to the targeted concern of Reglan exposure in occupational settings. Reglan, a medication historically used for gastrointestinal conditions, carries known risks that become particularly relevant when considering cumulative exposure in production contexts. The shift from general health literacy to workplace safety awareness thus represents a logical progression, where the same foundational knowledge now informs risk assessment for those who manufacture rather than merely consume. Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. Its prescribing information carries a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Understanding Tardive Dyskinesia and Its Link to Reglan

The risk of developing TD increases with longer treatment duration and higher cumulative dosage. Reglan is contraindicated in patients with a history of TD, and the label instructs clinicians to use the drug for the shortest duration necessary and to reassess the need for continued treatment regularly (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD includes involuntary, often disfiguring movements such as lip smacking, tongue protrusion, grimacing, and rapid eye blinking. In some cases, movements may involve the trunk or extremities. The condition can be partially or fully suppressed by metoclopramide itself, which may delay diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the basal ganglia, leading to upregulation of these receptors and subsequent hypersensitivity. This dysregulation of motor control pathways results in the abnormal involuntary movements characteristic of TD.

Reglan Usage Guidelines and Risk Factors

Reglan is indicated only for short-term treatment: 4 to 12 weeks for gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label explicitly states that Reglan has not been shown to be safe or effective for gastroesophageal reflux beyond 12 weeks, and that use in pediatric patients is not recommended due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, clinicians should routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. This has led to a significant number of TD diagnoses linked to Reglan use.

Legal Considerations and Statute of Limitations in California

The adequacy of warnings regarding Reglan and TD has been a central issue in litigation. The boxed warning, while present in the label, may not have been effectively communicated to all prescribers or patients. Some patients report that they were not informed of the risk of TD before starting treatment, or that they were not monitored for early signs of the condition. The label does instruct that if signs or symptoms of TD occur, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be masked by the drug itself, early detection is challenging. For affected patients in California, the statute of limitations for filing a Reglan TD lawsuit is a critical consideration. In California, the statute of limitations for personal injury claims is generally two years from the date of injury. However, for claims involving latent harm, such as TD, the discovery rule applies: the clock starts when the plaintiff knew or should have known that their injury was caused by the drug. This means that the statute of limitations may begin when a patient is diagnosed with TD or when they first notice symptoms and suspect a link to Reglan. Given that TD can develop months or years after starting Reglan, and symptoms may be subtle initially, the timeline between exposure and documented harm can be prolonged. Patients who were prescribed Reglan for longer than 12 weeks are at higher risk, and those who developed TD after such extended use may have a stronger claim.

Settlement Considerations and Next Steps

Settlement-related considerations for affected patients include the need to document the duration of Reglan use, the cumulative dosage, and the timing of TD diagnosis. Medical records should show that the patient was prescribed Reglan for an approved indication, that the duration exceeded label recommendations, and that TD symptoms were documented by a neurologist or movement disorder specialist. The presence of a boxed warning does not automatically absolve the manufacturer of liability if the warning was inadequate or if the drug was marketed for longer-term use without proper safeguards. In many cases, settlements have been reached for patients who developed TD after using Reglan for extended periods, particularly when the manufacturer failed to adequately warn about the risk of irreversible movement disorders. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the date of diagnosis and the date they first learned of the potential link between Reglan and TD. The statute of limitations in California may bar claims if too much time has passed since the injury was discovered. Therefore, prompt action is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan Tardive Dyskinesia claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury. However, for latent harm like Tardive Dyskinesia, the discovery rule applies, meaning the clock starts when the patient knew or should have known that their injury was caused by Reglan. This could be the date of diagnosis or when symptoms were first linked to the drug.

Can I still file a lawsuit if I was prescribed Reglan for more than 12 weeks?

Yes, especially if you developed Tardive Dyskinesia after extended use. The label warns against use beyond 12 weeks, and longer use increases risk. Documenting the duration and dosage is crucial for a potential claim.

What evidence do I need for a Reglan TD settlement?

You need medical records showing Reglan prescription for an approved indication, duration exceeding label recommendations, and a Tardive Dyskinesia diagnosis from a neurologist or movement disorder specialist. Also, records of when you first noticed symptoms and linked them to Reglan.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.